Luciferase reporter assays are commonly used in high-throughput screening methods. Here, we report new firefly luciferase (FLuc) inhibitors based on 5-benzyl-3-phenyl-4,5-dihydroisoxazoles and 5-benzyl-3-phenyl-1,4,2-dioxazoles, which showed up as "false positives" in a luciferase reporter gene-based assay for nuclear receptor antagonists. The inhibition was shown to be noncompetitive for both natural enzyme substrates (d-luciferin and ATP) and selective to FLuc and proven to arise from a direct interaction between the enzyme and the inhibitor. Of the 63 evaluated compounds, 28 showed significantly better inhibition potency than the well-known inhibitor resveratrol (IC(50) = 59 nM), with five compounds having distinctly subnanomolar IC(50) values. The most efficient compounds inhibited the luminescence at concentrations lower than (1)/(100) in comparison to resveratrol (lowest IC(50) = 0.26 nM) and can thus be considered to belong to the most potent FLuc inhibitors reported thus far. Overall, the novel inhibitors form a unique molecular library for structure-activity relationship (SAR) analyses.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm301516qDOI Listing

Publication Analysis

Top Keywords

5-benzyl-3-phenyl-45-dihydroisoxazoles 5-benzyl-3-phenyl-142-dioxazoles
8
firefly luciferase
8
luciferase reporter
8
fluc inhibitors
8
discovery 5-benzyl-3-phenyl-45-dihydroisoxazoles
4
5-benzyl-3-phenyl-142-dioxazoles potent
4
potent firefly
4
luciferase
4
inhibitors
4
luciferase inhibitors
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!